Protocol Title: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Target Population: Urothelial Carcinoma / Transitional Cell Carcinoma of the Urothelium

Summary: The purpose of the ATLAS study is to determine how patients with locally advanced or metastatic Urothelial Carcinoma respond to treatment with Rucaparib.

Key Inclusion Criteria:
- Have histologically or cytologically confirmed locally advanced or metastatic Transitional Cell Carcinoma of the Urothelium (Renal Pelvis, Ureter, Urinary Bladder or Urethra)
- Received 1 or 2 prior standard of care regimens for advanced or metastatic disease
- Confirmed radiologic disease progression during or following recent treatment
- Mandatory biopsy is required during screening
- Measurable disease per RECIST v1.1
- Adequate organ function
- ECOG Performance Score 0 or 1

Key Exclusion Criteria:
- Prior treatment with a PARP Inhibitor
- Symptomatic and/or untreated CNS Metastases
- Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of Rucaparib

Contacts:
- Principal Investigator: Marc Matrana, MD
- Research Nurses (RN): Jessica Rentfrow (jessica.rentfrow@ochsner.org, ext. 32652)
  Amanda Woolery (amanda.woolery@ochsner.org, ext. 20275)

For additional information: https://clinicaltrials.gov/ct2/show/NCT03397394